Comparison of the Efficacies of Parenteral Iron Sucrose and Oral Iron Sulfate for Anemic Patients with Inflammatory Bowel Disease in Korea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The optimal route for iron administration in anemic patients with inflammatory bowel disease (IBD) has not been determined. The aim of this study was to compare the efficacies of parenteral and oral iron therapy in IBD patients in Korea. Methods: A retrospective multicenter study was performed. Patients who had been administered parenteral iron were matched to the controls with oral iron at a 1:1 ratio according to age, sex, and type of IBD. Results: Patients that received parenteral iron exhibited increases in hemoglobin levels of ≥20% from the baseline at lower doses and in shorter durations (p=0.034 and p=0.046, respectively). In the multivariate analysis, parenteral iron therapy appeared to be more efficient than oral iron therapy, but this difference was not statistically significant (hazard ratio [HR], 1.552; 95% confidence interval [CI], 0.844 to 2.851; p=0.157). Patients with ulcerative colitis responded better to iron therapy than those with Crohn’s disease (HR, 3.415; 95% CI, 1.808 to 6.450; p<0.001). Patients with an initial hemoglobin level of 10 g/dL or higher responded poorly to iron therapy (HR, 0.345; 95% CI, 0.177 to 0.671; p=0.002). Conclusions: Parenteral iron therapy appears to be more efficient than oral iron therapy. Physicians should focus on the iron deficiency of IBD patients and consider parenteral iron supplements in appropriate patient groups.
Abstract
Background/Aims: The optimal route for iron administration in anemic patients with inflammatory bowel disease (IBD) has not been determined. The aim of this study was to compare the efficacies of parenteral and oral iron therapy in IBD patients in Korea. Methods: A retrospective multicenter study was performed. Patients who had been administered parenteral iron were matched to the controls with oral iron at a 1:1 ratio according to age, sex, and type of IBD. Results: Patients that received parenteral iron exhibited increases in hemoglobin levels of ≥20% from the baseline at lower doses and in shorter durations (p=0.034 and p=0.046, respectively). In the multivariate analysis, parenteral iron therapy appeared to be more efficient than oral iron therapy, but this difference was not statistically significant (hazard ratio [HR], 1.552; 95% confidence interval [CI], 0.844 to 2.851; p=0.157). Patients with ulcerative colitis responded better to iron therapy than those with Crohn’s disease (HR, 3.415; 95% CI, 1.808 to 6.450; p<0.001). Patients with an initial hemoglobin level of 10 g/dL or higher responded poorly to iron therapy (HR, 0.345; 95% CI, 0.177 to 0.671; p=0.002). Conclusions: Parenteral iron therapy appears to be more efficient than oral iron therapy. Physicians should focus on the iron deficiency of IBD patients and consider parenteral iron supplements in appropriate patient groups.
참고문헌 (25)
- Schreiber S, "Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease", N Engl J Med, 334, pp.619~623 (1996)
- Cucino C, "Cause of death in patients with inflammatory bowel disease", Inflamm Bowel Dis, 7, pp.250~255 (2001)
- Pizzi LT, "Impact of chronic conditions on quality of life in patients with inflammatory bowel disease", Inflamm Bowel Dis, 12, pp.47~52 (2006)
- Wells CW, "Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients", Inflamm Bowel Dis, 12, pp.123~130 (2006)
- Cronin CC, "Anemia in patients with chronic inflammatory bowel disease", Am J Gastroenterol, 96, pp.2296~2298 (2001)
- Kulnigg S, "Systematic review: managing anaemia in Crohn’s disease", Aliment Pharmacol Ther, 24, pp.1507~1523 (2006)
- Ott C, "High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a populationbased cohort", Gastroenterol Res Pract, 2012, pp.595970~ (2012)
- Gisbert JP, "Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement", Inflamm Bowel Dis, 15, pp.1485~1491 (2009)
- Danese S, "Anaemia from a patient perspective in inflammatory bowel disease: results from the European Federation of Crohn’s and Ulcerative Colitis Association’s online survey", Eur J Gastroenterol Hepatol, 26, pp.1385~1391 (2014)
- Lee TW, "Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis", J Crohns Colitis, 6, pp.267~275 (2012)
- Avni T, "Treatment of anemia in inflammatory bowel disease: systematic review and meta-analysis", PLoS One, 8, pp.e75540~ (2013)
- Gasche C, "Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases", Inflamm Bowel Dis, 13, pp.1545~1553 (2007)
- Dignass AU, "European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases", J Crohns Colitis, 9, pp.211~222 (2015)
- Kulnigg S, "A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial", Am J Gastroenterol, 103, pp.1182~1192 (2008)
- Lindgren S, "Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluatorblind, multicentre study", Scand J Gastroenterol, 44, pp.838~845 (2009)
- Schröder O, "Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease: a randomized, controlled, open-label, multicenter study", Am J Gastroenterol, 100, pp.2503~2509 (2005)
- Erichsen K, "Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease", Scand J Gastroenterol, 40, pp.1058~1065 (2005)
- Yoon Jae Kim, "Intravenous Iron and Oral Iron Treatment in Anemia of Inflammatory Bowel Disease", Intestinal research, 11(3), pp.227~228 (2013), 대한장연구학회
- 예병덕, "크론병 진단 가이드라인", 대한소화기학회지, 53(3), pp.161~176 (2009), 대한소화기학회
- 최창환, "궤양성 대장염 진단 가이드라인", 대한소화기학회지, 53(3), pp.145~160 (2009), 대한소화기학회
- Geisser P, "The pharmacokinetics and pharmacodynamics of iron preparations", Pharmaceutics, 3, pp.12~33 (2011)
- Kaushansky K, "Williams Hematology" (2010), McGraw-Hill Education LLC
- Naito Y, "Adaptive response of the heart to long-term anemia induced by iron deficiency", Am J Physiol Heart Circ Physiol, 296, pp.H585~H593 (2009)
- Reinisch W, "A randomized, openlabel, non-inferiority study of intravenous iron isomaltoside 1,000(Monofer) compared with oral iron for treatment of anemia in IBD (Proceed)", Am J Gastroenterol, 108, pp.1877~1888 (2013)
- Ganzoni AM, "Intravenous iron-dextran: therapeutic and experimental possibilities", Schweiz Med Wochenschr, 100, pp.301~303 (1970)